News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chronogen Inc. Names Mr. Kees Been, Chief Executive Officer Of Bionaut Pharmaceuticals, Inc. To Board Of Directors


10/19/2005 5:10:57 PM

MONTREAL, April 20 /PRNewswire/ -- Chronogen Inc. (http://www.chronogen-inc.com/), a drug discovery company developing human therapeutics to treat age-dependent diseases, announced today the appointment of Mr. Kees Been, to the company's Board of Directors.

Mr. Been is Chief Executive Officer of Bionaut Pharmaceuticals, a pioneering company using a highly predictive, cell-based assay platform, for small molecule drug discovery and lead optimization. He most recently served as Senior Vice President of Biogen's Oncology Business Unit, after having been responsible for all of Biogen's activities in business development, mergers and acquisitions, corporate strategy and portfolio management for a 2-year period. Prior to this, he held various executive positions related to international growth strategy with Monsanto Life Sciences and was responsible for building the pharmaceuticals practice of Gemini consulting until 1995. Mr. Been holds an MBA from INSEAD in France and a Masters of Biotechnology from the University of Agriculture, The Netherlands.

"Mr. Been brings proven track record and expertise in business development, portfolio management and corporate strategy from life science industry, enabling us to benefit from his experience to advance our company quickly" said Iraj Beheshti, President and CEO of Chronogen. "We are delighted to benefit from Mr. Been's world-class management experience".

ABOUT CHRONOGEN Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging in whole model organisms has provided very valuable assets for a drug discovery technology that will lead to novel and efficacious drugs in significant markets including atherosclerosis, vascular complications of diabetes, and ischemia/reperfusion injuries. Chronogen is headquartered in Montreal, Canada. Further information can be found at http://www.chronogen-inc.com/

CHRONOGEN INC.

CONTACT: Iraj Beheshti, President & CEO, (514)-521-9595,ext. 202, ibeheshti@chronogen-inc.com; Marie-Lise Gauthier, Vice Presidentof Finance, (514) 21-9595, ext.206, mlgauthier@chronogen-inc.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES